IP Library Granted Patent US 8,986,609
Granted Patent B2
US 8,986,609 · App. 13/505,214 · Granted Mar 24, 2015

Sterilization of biodegradable hydrogels

Inventors: Harald Rau (Dossenheim, DE); Tobias Voigt (Heidelberg, DE); Ulrich Hersel (Heidelberg, DE)
Assignee: Ascendis Pharma A/S
A61K47/48784A61K41/0019A61L2/0035A61L2/081A61L2/10C08G65/329C08L71/02A61L2202/21C08L2203/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,986,609
App. No.
13/505,214
Granted
Mar 24, 2015
Kind
B2
Abstract

The present invention relates to a terminal sterilization process for biodegradable PEG-based insoluble hydrogels using irradiation. The presence of a protective solvent ensures that the hydrogel remains intact with functionally preserved three-dimensional and physicochemical properties.

Claims (43)

1. A method for sterilizing a biodegradable poly(ethylene glycol) based insoluble hydrogel comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the method comprising the steps of:

(a) providing the hydrogel;

(b) solvating the hydrogel in a protective solvent, or in a mixture of the protective solvent with another protective solvent, or in an aqueous solution thereof; and

(c) subjecting the solvated hydrogel, in the presence of the protective solvent, to gamma radiation;

wherein the protective solvent comprises at least one component selected from the group consisting of NMP, DMA, DME and DMI; and

wherein the protective solvent optionally contains one or more protecting agents.

2. The method of claim 1 ;

wherein the protective solvent comprises NMP.

3. The method of claim 1 ;

wherein sterilization is obtained with gamma radiation with a dose of from 5 to 100 kGy.

4. The method of claim 1 ;

wherein sterilization is obtained with gamma radiation with a dose of from 8 to 50 kGy.

5. The method of claim 1 ;

wherein the hydrogel is loaded with small molecule biologically active moieties.

6. The method of claim 1 ;

wherein the backbone moieties of the hydrogel have each a molecular weight in the range of from 1 kDa to 20 kDa.

7. The method of claim 1 ;

wherein the backbone moieties of the hydrogel are interconnected by hydrolytically degradable bonds; and

wherein the backbone moieties are linked together through crosslinker moieties, each crosslinker moiety being terminated by at least two of the hydrolytically degradable bonds.

8. The method of claim 1 ;

wherein the hydrolytically degradable bonds are carboxylic esters, carbonates, phosphoesters, or sulfonic acid esters.

9. The method of claim 7 ;

wherein the crosslinker moieties have a molecular weight in the range of from 60 Da to 5 kDa.

10. The method of claim 1 ;

wherein the backbone moieties of the biodegradable PEG based insoluble hydrogel comprise a branching core of the following formula:

wherein the dashed line indicates attachment to the remainder of the backbone moiety.

11. The method of claim 1 ;

wherein the backbone moieties of the biodegradable PEG based insoluble hydrogel comprise a structure of the following formula:

wherein n is an integer of from 5 to 50, and the dashed line indicates attachment to the rest of the molecule.

12. The method of claim 1 ;

wherein the backbone moieties of the biodegradable PEG based insoluble hydrogel comprise a hyperbranched moiety Hyp.

13. The method of claim 12 ;

wherein the backbone moieties of the biodegradable PEG based insoluble hydrogel comprise a hyperbranched moiety Hyp of the following formula:

wherein the dashed lines indicate attachment to the rest of the molecule and carbon atoms marked with asterisks indicate S-configuration.

14. The method of claim 12 ;

wherein the backbone moieties are attached to at least one spacer of the following formula:

wherein one of the dashed lines indicates attachment to the hyperbranched moiety Hyp, and the second dashed line indicates attachment to the rest of the molecule; and

wherein m is an integer of from 2 to 4.

15. The method of claim 1 ;

wherein the backbone moieties are linked together through crosslinker moieties comprising the following structure:

wherein q is an integer from 3 to 100.

16. The method of Claim 1 ;

wherein the protecting agents are selected from propylamine, butylamine, pentylamine, Sec, butylamine, ethanolamine, diethanolamine, serinol, trishydroxymethyl-aminomethane, acetic acid, formic acid, ascorbic acid, glycineamide, pivalic acid, propanoic acid, succinic acid, glutaric acid, adipic acid, thioglycerin, dithiothreitol, mercaptoethanol, and reduced glutathione.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME PREVIOUSLY RECORDED AT REEL: 046582 FRAME: 0197. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Aug 9, 2018
From: ASCENDIS PHARMA GMBH
To: ASCENDIS PHARMA A/S
Reel/Frame 046756/0007 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2018
From: RAU, HARALD, DR; VOIGT, TOBIAS, DR.; HERSEL, ULRICH, DR.
To: ASCENDIS PHARMA GMBH
Reel/Frame 046582/0127 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2018
From: ASCENDIS PHARMA A/S
To: ASCENDIS PHARMA A/S
Reel/Frame 046582/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2012
From: RAU, HARALD, DR.; VOIGT, TOBIAS, DR.; HERSEL, ULRICH, DR.
To: ASCENDIS PHARMA AS
Reel/Frame 028336/0748 →
Priority Claims (1)
EP 09174526 · Oct 29, 2009 · regional
Continuity (1)
Related Publication 20120253071A1 · Oct 4, 2012